Financials

  • Market Capitalization 335.77 M
  • Employee 128
  • Founded 2003
  • CEO N/A
  • Website www.sutrobio.com
  • Headquarter California, United States
  • FIGI BBG000R4V3P3
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.51
Price to sales ratio
0.96

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3227
SABS
SAB Biotherapeutics, Inc. - Common Stock
3.70 USD-2.12%-1.60%+4.82%+75.36%336.65 M USD
3228
IMRX
Immuneering Corporation - Class A Common Stock
5.21 USD-1.70%+2.36%+18.95%+8.54%337.07 M USD
3240
YDES
YD Bio Limited - Ordinary Shares
4.77 USD+1.71%+48.14%+115.84%-40.38%337.66 M USD
3254
OBIO
Orchestra BioMed Holdings, Inc. - Ordinary Shares
5.46 USD+1.87%+20.53%+43.68%+114.12%328.17 M USD

Frequently asked questions about Sutro Biopharma, Inc.

What is the Sutro Biopharma, Inc. stock price today?

The current price of Sutro Biopharma, Inc. (STRO) is 20.25. Over the past 24 hours, the stock has changed by -3.75%. Follow the STRO chart for real-time price dynamics.

What is the stock ticker of Sutro Biopharma, Inc.?

Sutro Biopharma, Inc. trades under the ticker STRO. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Sutro Biopharma, Inc. stock going up?

STRO has changed by -2.69% over the last week, -11.88% over the last month, and +16.45% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Sutro Biopharma, Inc.?

Sutro Biopharma, Inc. currently has a market capitalization of 335.77 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Sutro Biopharma, Inc. earnings last quarter?

Last quarter, Sutro Biopharma, Inc. reported earnings of -2.33 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Sutro Biopharma, Inc. revenue for the last quarter?

Sutro Biopharma, Inc. reported quarterly revenue of 9.84 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Sutro Biopharma, Inc. net income for the last quarter?

Sutro Biopharma, Inc. reported net income of -38.53 M for the last quarter. The previous quarter showed -38.48 M, which means net income changed by -0.13%.

How many employees does Sutro Biopharma, Inc. have?

As of the latest available data, Sutro Biopharma, Inc. has 128 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Sutro Biopharma, Inc. stock?

You can buy Sutro Biopharma, Inc. (STRO) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Sutro Biopharma, Inc. stock?

Investing in Sutro Biopharma, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the STRO chart and related analysis on metatrader.com as part of your research.

Sutro Biopharma, Inc. - Common Stock

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

News